MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sale and maturities of available...
Depreciation and amortization ex...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchase of available for sale s...
Payments on convertible debentur...
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,423
-8,303
-7,933
-8,504
Depreciation and amortization expense
2,296
2,310
2,337
2,376
Inventory write-offs
-
-
0
0
Amortization of financing lease right-of-use asset
51
51
51
51
Gain on lease termination/modification
-
-
-
0
Accretion of interest on securities
109
194
249
236
Net realized loss on investments
-
-
0
0
Non-cash lease expense
-8
122
-81
392
Gain on lease modification
-
0
450
-
Gain on lease termination/modification
0
-
-
-
Stock-based compensation
970
670
926
941
Cost of leased equipment sold to customer
96
50
356
133
Change in fair value of contingent consideration
-
-
0
0
Change in fair value of convertible debentures
-114
-173
-154
62
Loss on issuance of convertible debentures
-
-
0
0
Gain on high trail extinguishment
-
-
0
0
Loss on extinguishment of convertible debentures payable
-
-
0
-
Disposal of internal-use software
-
-
0
0
Intangible assets and other long-lived assets impairment
-
-
0
0
Long-lived assets held for sale impairment
-
-
0
-
Right-of-use-asset impairment
-
-
0
0
Disposal of property and equipment
0
-34
0
0
Accounts receivable
233
-1,067
674
1,031
Inventory
-77
106
-1,574
-1,508
Prepaid expenses and other current assets
26
-339
-173
2,280
Other assets
-
-
-
-326
Other long-term assets
-575
-16
-60
-
Accounts payable
-500
-528
-399
-254
Accrued expenses, contract liabilities, and lease liabilities, net
-550
-1,417
522
721
Net cash used in operating activities
-4,670
-5,716
-4,175
-5,919
Purchases of property and equipment
-
-
0
0
Purchase of available for sale securities
31,459
48,672
64,352
60,885
Sale and maturities of available for sale securities
45,140
54,129
68,361
56,216
Net cash provided by (used in) investing activities
13,681
5,457
4,009
-4,669
Principal payments of financing lease liability
21
20
18
19
Proceeds from sale of common stock and warrants
620
705
1,751
12,939
Offering expenses on sale of common stock and warrants
26
28
130
969
Proceeds from sale of common stock under employee stock purchase plan
-
-
0
0
Proceeds from warrant and option exercises
0
0
0
0
Proceeds from issuance of convertible debentures
-
-
0
0
Payments on high trail notes
-
-
0
0
Payments on convertible debentures
10,266
0
0
1,875
Debt issuance costs on sale of convertible debentures
-
-
0
0
Payments of retirement fees for redemption of high trail notes
-
-
0
0
Net cash provided by (used in) financing activities
-9,693
657
1,603
10,076
Effect of exchange rates on cash and cash equivalents and restricted cash
1
5
7
15
Net increase (decrease) in cash and cash equivalents and restricted cash
-681
403
1,444
-497
Cash and cash equivalents and restricted cash at beginning of period
4,912
4,509
3,065
9,573
Cash and cash equivalents and restricted cash at end of period
4,231
4,912
4,509
3,065
Cash and cash equivalents
3,730
-
-
-
Restricted cash
501
-
-
-
Total cash and cash equivalents and restricted cash at end of period
4,231
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sale and maturities
of available for...
$45,140K
(-56.83%↓ Y/Y)
Net cash provided by
(used in) investing...
$13,681K
(213.19%↑ Y/Y)
Effect of exchange
rates on cash and cash...
$1K
(103.03%↑ Y/Y)
Canceled cashflow
$31,459K
Net increase
(decrease) in cash and cash...
-$681K
(88.67%↑ Y/Y)
Canceled cashflow
$13,682K
Proceeds from sale of
common stock and...
$620K
(-96.22%↓ Y/Y)
Depreciation and
amortization expense
$2,296K
(-52.31%↓ Y/Y)
Stock-based compensation
$970K
(-63.63%↓ Y/Y)
Other long-term
assets
-$575K
Change in fair value of
convertible debentures
-$114K
(-102.17%↓ Y/Y)
Cost of leased
equipment sold to customer
$96K
(-55.35%↓ Y/Y)
Inventory
-$77K
(95.80%↑ Y/Y)
Amortization of financing
lease right-of-use...
$51K
(-50.00%↓ Y/Y)
Purchase of available for
sale securities
$31,459K
(-73.03%↓ Y/Y)
Net cash provided by
(used in) financing...
-$9,693K
(-178.42%↓ Y/Y)
Canceled cashflow
$620K
Net cash used in
operating activities
-$4,670K
(25.29%↑ Y/Y)
Canceled cashflow
$4,179K
Payments on convertible
debentures
$10,266K
(242.20%↑ Y/Y)
Offering expenses on sale
of common stock and...
$26K
(-97.46%↓ Y/Y)
Principal payments of
financing lease liability
$21K
(-38.24%↓ Y/Y)
Net loss
-$7,423K
(25.46%↑ Y/Y)
Accrued expenses,
contract liabilities,...
-$550K
(69.83%↑ Y/Y)
Accounts payable
-$500K
(30.46%↑ Y/Y)
Accounts receivable
$233K
(118.54%↑ Y/Y)
Accretion of interest on
securities
$109K
(-77.80%↓ Y/Y)
Prepaid expenses and
other current assets
$26K
(157.78%↑ Y/Y)
Non-cash lease expense
-$8K
(-101.37%↓ Y/Y)
Buy us a coffee
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)